Hans Kreipe - Concepedia

Author

Hans Kreipe

Also Known As

Bu, Guntram Büsche, Gustavo Baretton, H H Kreipe, H Kreipe, H. H. Kreipe, H. Kreipe, H.-H. Kreipe, H.H. KREIPE, H.H. Kreipe

711

Publications

24.3K

Citations

H-Index

228

Concepts

All Affiliations

Medizinische Hochschule Hannover Ludwig-Maximilians-Universität München Charité - Universitätsmedizin Berlin Kliniken Essen-Mitte Deutsches Archäologisches Institut, Zentrale

About

Hans Kreipe is an author at Medizinische Hochschule Hannover specializing in medicine, pathology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	53	172	9.5K
2	Health Sciences	17	21	909
3	Engineering	8	8	395
4	Natural Sciences	8	8	378
5	Public Health	4	4	302

Hans Kreipe

311

Publications

20.6K

Citations

H-Index

Page 1

	Year	Citations
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor Erik‐Oliver Glocker, Daniel Kotlarz, Kaan Boztuǧ, New England Journal of Medicine	2009	1.4K
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group Torsten O. Nielsen, Samuel Leung, David L. Rimm, JNCI Journal of the National Cancer Institute	2020	673
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing Josef Rüschoff, Manfred Dietel, Gustavo Baretton, Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin	2010	486
Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy Daniel Kotlarz, Rita Beier, Dhaarini Murugan, Gastroenterology InflammationCytokineMucosal ImmunologyImmunologyGastroenterology	2012	462
Epigenetic inactivation of microRNA gene <i>hsa‐mir‐9‐1</i> in human breast cancer Ulrich Lehmann, Britta Hasemeier, Matthias Christgen, The Journal of Pathology	2007	458
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Nadia Harbeck, Priya Rastogi, Miguel Martín, Annals of Oncology	2021	364
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment Oleg Gluz, Ulrike Nitz, Matthias Christgen, Journal of Clinical Oncology	2016	357
Trastuzumab emtansine (T-DM1) renders HER2 <sup>+</sup> breast cancer highly susceptible to CTLA-4/PD-1 blockade Philipp Müller, Matthias Kreuzaler, Tarik A. Khan, Science Translational Medicine Breast OncologyImmunologyRegulatory T CellsCell PolarizationImmunotherapeutics	2015	328
The phenotype of human STK4 deficiency Hengameh Abdollahpour, Giridharan Appaswamy, Daniel Kotlarz, Blood	2012	321
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group Carsten Denkert, Stephan Wienert, Audrey Poterie, Modern Pathology Tumor ImmunologyBreast OncologyCancer ImmunosurveillanceMedicineImmunology	2016	268

Page 1